The (S)-crizotinib enantiomer inhibits MTH1 activity Because SCH51344 has not been evaluated in a clinical setting, we decided to screen for other, more potent MTH1 inhibitors with favourable
Activated RAS GTPase signalling is a critical driver of oncogenic transformation and malignant disease. Cellular models of RAS-dependent cancers have been used to identify experimental small molecules, such as SCH51344, but their molecular mechanism of action remains generally unknown. Here, using a chemical proteomic approach, we identify the target of SCH51344 as the human mutT homologue MTH1 (also known as NUDT1), a nucleotide pool sanitizing enzyme. Lossof-function of MTH1 impaired growth of KRAS tumour cells, whereas MTH1 overexpression mitigated sensitivity towards SCH51344. Searching for more drug-like inhibitors, we identified the kinase inhibitor crizotinib as a nanomolar suppressor of MTH1 activity. Surprisingly, the clinically used (R)-enantiomer of the drug was inactive, whereas the (S)-enantiomer selectively inhibited MTH1 catalytic activity. Enzymatic assays, chemical proteomic profiling, kinomewide activity surveys and MTH1 co-crystal structures of both enantiomers provide a rationale for this remarkable stereospecificity. Disruption of nucleotide pool homeostasis via MTH1 inhibition by (S)-crizotinib induced an increase in DNA single-strand breaks, activated DNA repair in human colon carcinoma cells, and effectively suppressed tumour growth in animal models. Our results propose (S)-crizotinib as an attractive chemical entity for further pre-clinical evaluation, and small-molecule inhibitors of MTH1 in general as a promising novel class of anticancer agents.
Mutations in RAS isoforms are prevalent in human cancers, accompanied by poor prognosis and low survival, highlighting the need to develop new therapies [1] [2] [3] . Direct modulation of RAS activity has posed a significant challenge in drug discovery. Therefore, alternative approaches have been used, for example by interfering with RAS posttranslational modifications to prevent maturation and translocation of the active protein to the plasma membrane [4] [5] [6] . In addition, phenotypic screens have been used to search for small molecules that selectively target RAS-transformed cancer cells 7 . In 1995, this led to the discovery of a compound termed SCH51344 that suppressed the anchorage-independent growth of RAStransformed fibroblasts 8 . As SCH51344 did not affect MAPK signalling, which is thought to be the primary mediator of RAS oncogenic activity, a novel but enigmatic mode of action was proposed 9 .
Identification of MTH1 as the main target of SCH51344
We set out to identify the cellular targets of SCH51344 using a chemical proteomic strategy (Fig. 1a ). We generated a SCH51344 affinity probe ( Fig. 1b ) which we incubated with lysates of KRAS-positive SW480 cells, which are sensitive to SCH51344, and analysed the binding proteins by mass spectrometry. High-affinity binders were discriminated against highly abundant low-affinity proteins by competition with the free unmodified compound. Bioinformatic analysis revealed the human 7,8-dihydro-8-oxoguanine triphosphatase MTH1 (also known as NUDT1) and adenosine kinase (ADK) as the primary cellular targets of SCH51344 ( Fig. 1c ). MTH1 has been implicated in aiding RAS-transformed cells to overcome oncogeneinduced senescence by preventing reactive oxygen species (ROS)-induced DNA damage 10 . On the contrary, little was known about the role of ADK in malignant disease, but in line with published RNA interference data 11 we did not observe any growth impairment of SCH51344-sensitive 8 PANC1 human pancreatic carcinoma cells upon treatment with the ADK inhibitor ABT-702 (data not shown). We therefore focused on MTH1 as the most likely relevant target of SCH51344. Having confirmed the binding of SCH51344 to MTH1 in both SW480 and DLD1 cells by immunoblot (Extended Data Fig. 1a ), we used isothermal titration calorimetry (ITC) to determine a K d value of 49 nM for SCH51344 ( Fig. 1d and Extended Data Fig. 1b ). MTH1 is a homologue of the bacterial mutT, a nucleotide pool sanitizing enzyme which cleaves oxidized nucleotides such as 8-oxodeoxyguanosinetriphosphate (8-oxo-dGTP), thereby converting the triphosphates into the corresponding monophosphates 12 . The hydrolysis reaction ensures that the oxidized nucleotides can no longer be recognized by DNA polymerase, preventing the mispairing of bases during replication and thus transversion mutations 13, 14 . To investigate the effect of SCH51344 on MTH1 catalytic activity we monitored the production of pyrophosphate (PPi) as a result of nucleotide triphosphate hydrolysis 15 . We determined half-maximum inhibitory concentration (IC 50 ) values of 215 nM, 410 nM and 675 nM for SCH51344 against the MTH1 substrates dGTP, 8-oxo-dGTP and 2-OH-dATP, respectively, confirming a direct effect of SCH51344 on MTH1 catalytic activity ( Fig. 1e ). To validate MTH1 as the causal target for the antiproliferative effects of SCH51344, we transfected human SW480 and DLD1 cells with NUDT1 (MTH1) short interfering RNA that impaired colony formation ( Fig. 1f ). Stable knockdown using lentiviral short hairpin RNAs 16 phenocopied results obtained using the inhibitor (Extended Data Fig. 1c ). Conversely, overexpression of MTH1 10 reduced sensitivity of SW480 cells against SCH51344 ( Fig. 1g and Extended Data Fig. 1d ), mechanistically corroborating the evidence that MTH1 is the main cellular target of SCH51344. pharmacokinetic and pharmacodynamic properties. On the basis of substrates and active site architecture we proposed that kinase inhibitors may target MTH1. Screening a kinase inhibitor collection in a thermal shift stability assay 17 we found that the dual c-MET/ALK inhibitor crizotinib 18, 19 exhibited high affinity towards MTH1 (data not shown). Crizotinib recently received approval for the treatment of EML4-ALKpositive non-small cell lung cancer (NSCLC) and is in several other clinical trials [20] [21] [22] [23] . However, using the catalytic MTH1 assay, we found that crizotinib batches obtained from different vendors resulted in varying IC 50 values. This could not be explained by impurities or degradation products as analytical data were in accordance with literature 18 . Because crizotinib bears a chiral centre, we speculated that variable amounts of crizotinib stereoisomers may occur in different batches of inhibitor. We prepared and tested both the pure, clinically used (R)-as well as the so far unexplored (S)-enantiomer of crizotinib in the MTH1 catalytic assay, which suggested that the screening hit batch contained a racemic mixture. We found that pure (S)-crizotinib was a low nanomolar MTH1 inhibitor whereas the (R)-enantiomer gave IC 50 values in the micromolar range ( Fig. 2a ). These data were confirmed by direct-binding assays (ITC), indicating a 16-fold higher affinity of the (S)-enantiomer towards MTH1 ( Fig. 2b and Extended Data Fig. 2a ). Using K m concentrations of substrates 12, 15 , we determined average IC 50 values of 330 nM and 408 nM for (S)-crizotinib and the MTH1 substrates 8-oxo-dGTP and 2-OH-dATP, respectively (n 5 2). Consistent with these data, (S)-crizotinib efficiently inhibited colony formation of SW480 cells and KRAS-mutated PANC1 cells, similar to SCH51344 ( Fig. 2c, d) . In vitro K d measurements indicated that (S)-crizotinib was considerably less potent than the (R)enantiomer against the established targets ALK, MET and ROS1 (Extended 
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Data Fig. 2b ). Treatment of SW480 cells with a specific c-MET inhibitor, a potential off-target for (S)-crizotinib 18 , did not lead to the detection of any significant effects on proliferation (Extended Data Fig. 2c ). However, investigating whether MTH1 overexpression could rescue SW480 cells from cell death induced by (S)-crizotinib in a similar manner as for SCH51344, we failed to observe any significant shift in IC 50 values (Extended Data Fig. 2d ), raising the question whether other targets contributed to the cell killing effect. We started investigating whether MTH1 was indeed targeted by (S)-crizotinib in intact cells. If a cellular protein is bound by a chemical agent, it is stabilized by the physical engagement compared to the non-engaged counterpart 24 . In a cellular thermal shift assay using BJ-KRASV12 cells, (S)-crizotinib, in contrast to (R)-crizotinib, efficiently stabilized MTH1 validating the differential targeting within cells ( Fig. 2e ).
Specificity of (S)-crizotinib and analysis of binding mode
To further investigate the ability of the two crizotinib enantiomers to engage cellular proteins, we derived chemical probes suitable for drug pull-downs (Supplementary Information). We tested two derivatized 
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compounds for their ability to target ALK and MTH1 in SW480 cell extracts. The two enantiomers were remarkably specific for their cognate targets ( Fig. 2f ). If MTH1 was indeed the key target of (S)-crizotinib in other RAS-transformed cells, it should rank at the top of the specific interactors in an unbiased chemical proteomic experiment as done before with SCH51344. MTH1 was by far the most specific and prominent interactor of (S)-crizotinib (Extended Data Fig. 2e ). Plotting the chemical proteomic results of SCH51344 and (S)-crizotinib against each other singled out MTH1 as the only common high-significance interactor (Fig. 3a) . We also performed the reciprocal analysis with (R)-crizotinib which identified a plethora of protein kinases, all efficiently competed by free drug, but not MTH1 (Extended Data Fig. 2f ). Notably, comparison of both profiles did not reveal any proteins that were significantly bound by both enantiomers (Fig. 3b ). To exclude that either crizotinib enantiomer may target kinases of low abundance we interrogated a panel of 456 different recombinant kinases (KINOMEscan, Extended Data Fig. 3 ) 25 . In line with the chemoproteomic results the two enantiomers showed a remarkable stereoselectivity with very distinct profiles. The few kinases to which (S)-crizotinib showed some affinity were not calculated to be significantly inhibited. (R)-Crizotinib not only bound to ten times more kinases, but was also predicted to efficiently inhibit at least ten of them, including the well characterized cognate targets ALK and MET, but also LCK, IRAK1, JAK3, LOK (also known as STK10) and SLK. To understand the differences in MTH1 binding, we cocrystallized both (R)-and (S)-crizotinib with recombinant protein. The structure revealed an unfavourable eclipsed conformation of the methyl group at the chiral centre and a chlorine substituent on the benzyl ring is likely to reduce the energetic favourability of (R)-crizotinib binding ( Fig. 3c, d and Extended Data Figs 4 and 5). ITC data confirmed that the difference in binding between (R)-and (S)-crizotinib was entirely entropic and therefore not due to different binding interactions with the protein (Fig. 2b ).
MTH1 inhibitors induce DNA damage in cancer cells
Because MTH1 is thought to prevent incorporation of oxidized nucleotides into DNA, we reasoned that our new MTH1 inhibitors should increase the content of genomic 8-oxo-guanine, and thus induce DNA damage. Immunofluorescence staining for both 53BP1 (also known as TP53BP1) and autophosphorylated ATM, specific markers for DNA damage, was increased in SW480 cells treated with MTH1 inhibitors (Fig. 4a and Extended Data Fig. 6a ). 53BP1 foci, which we also observed in cells transfected with MTH1-siRNA, were enriched in nuclei of cells with higher levels of 8-oxo-guanine owing to increased genomic incorporation (Extended Data Fig. 6b, c) . We also tried to quantify the oxidized nucleotides by high-performance liquid chromatography coupled with mass spectrometry; however, due to high experimental background, we failed to obtain reliable results. Because accumulation of 8-oxo-guanine should activate base-excision repair (BER) 16 and induce DNA singlestrand breaks, we tested our inhibitors in an alkaline comet assay. Both (S)-crizotinib as well as SCH51344, but not (R)-crizotinib, yielded a significant tail moment, similar to cells transfected with MTH1-siRNA ( Fig. 4b ). Addition of the purified 8-oxo-guanine-or 2-hydroxy-adeninespecific DNA glycosylases, OGG1 and MUTYH, increased tail moments for (S)-crizotinib markedly, providing evidence for strong accumulation of these lesions upon inhibitor treatment (Extended Data Fig. 6d ). MTH1 overexpression significantly reduced the number of DNA single-strand 
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breaks induced by (S)-crizotinib as well as SCH51344, but not by H 2 O 2 ( Fig. 4c and Extended Data Fig. 6e ), providing evidence for MTH1 being the functionally relevant target. To explore the role of p53 in the cellular response to MTH1 suppression 16 we created an SW480 Tet-on system 26 allowing for the inducible expression of p53 shRNAs and treated the cells with our inhibitors (Extended Data Fig. 7 ), which indicated a p53-independent mode of action. Treatment of SW480 cells expressing anti-MTH1 shRNA with the ATM-and ATR-inhibitors KU55933 and VE821, respectively, also did not display any differential effects (Extended Data Fig. 8 ). Similarly, Atm 2/2 mouse embryonic fibroblasts were equally sensitive to MTH1 inhibitors as their Atm-proficient counterparts. Investigating cell lines bearing additional mutations in DNA repair genes, we found that HCT116 cells deficient for p21 were particularly sensitive to (S)-crizotinib. We tested our inhibitors in BJ skin fibroblasts that were either wild type, immortalized by hTERT, or transformed by SV40T and/or mutant KRAS. Both SCH51344 and (S)-crizotinib showed highest toxicity towards the SV40T and KRASV12 cells (Extended Data Fig. 9 ). Importantly, when we treated wild type BJ cells with (R)-or (S)crizotinib, we found that the (S)-enantiomer did not show any increased toxicity on non-transformed cells. Among a panel of human cancer cell lines, we consistently observed a strong antiproliferative effect for (S)crizotinib, in line with its lower catalytic assay IC 50 value. To explore the in vivo potential of (S)-crizotinib to impair tumour growth we performed mouse xenograft studies using SW480 cells. These experiments indicated that (S)-crizotinib, but not the (R)-enantiomer, was able to impair overall tumour progression as well as specifically reduce tumour volume by more than 50% (Fig. 4d, e and Extended Data Fig. 10a-c) . This suggested that the two enantiomers have clearly diverse antitumour profiles and was consistent with their distinct molecular mechanism of action.
Targeting nucleotide pool homeostasis as cancer therapy
Increased levels of ROS in fast-proliferating cancer cells impair nucleotide pool homeostasis and contribute to mutations and DNA damage 10 . Removal of oxidized nucleotides by MTH1 may relieve cancer cells from proliferative stress and thereby represent a vulnerability factor and an attractive target for anticancer compounds (Fig. 4f) 27 . MTH1 levels are increased in RAS-expressing cancers (Extended Data Fig. 10d ) ranging from lung cancer 28, 29 to renal carcinoma 30 , supportive of the notion that there is a connection between oncogenic transformation and oxidative stress. A potential more global role of MTH1 in tumorigenesis is supported by the observed antiproliferative effects for the inhibitors on cancer cells transformed by mechanisms other than RAS mutations (Extended Data Fig. 9c) 8 . Although prolonged clinical application will need to be evaluated critically in light of an increased long-term tumour burden in Mth1 2/2 (also known as Nudt1 2/2 ) mice, the mild phenotype of these knockout animals 31 , and the specificity of MTH1 inhibitors speak for an appropriate therapeutic window. We propose that MTH1, together with other enzymes controlling sanitization of oxidized nucleotides, may represent a new attractive targeting strategy for difficult-to-treat tumours that display high levels of replicative and oxidative stress. The identification of the chemical mirror image of a recently clinically approved anticancer agent, crizotinib, as a nanomolar inhibitor of a yet pharmacologically unexploited cellular process, argues for further high-priority pre-clinical and clinical studies. A thorough investigation of the pharmacodynamics and pharmacokinetic properties of (S)-crizotinib will be necessary to understand why overexpression of MTH1 failed to rescue its cell-killing effects under the conditions tested. Until then, the possibility remains that targets other than MTH1 contribute to the effects of (S)-crizotinib. Whereas (S)-crizotinib is technically a new chemical entity and would require a new, separate drug approval process, the fact that it differs from a safe and bioavailable drug only in one chiral centre makes it somewhat more likely to have favourable, drug-like properties 32 and thus may be auspicious for an efficient evaluation of the potential therapeutic merits.
METHODS SUMMARY
Drug-affinity matrices were prepared by immobilizing 25 nmol of compound on 50 ml N-hydroxysuccinimide (NHS)-activated Sepharose 4 Fast Flow beads (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Detailed procedures for affinity chromatography, elution and mass spectrometry analyses are provided in the supporting information.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell culture. BJ, H1437, H2122, H23, H358, H460, HCT116 and U2OS cells were obtained from ATCC and DMSZ. SW480, DLD1 and SW620 cells were kindly provided by W. Berger, PANC1 were a gift from R. Oehler. The BJ-hTERT, BJ-SV40T and BJ-RASV12 were provided by W. Hahn. HCT116 p53 2/2 and HCT116 p21 2/2 were used by permission of B. Vogelstein. LoVo and HCT15 were a gift from C. Gasche. Atm wild type and Atm 2/2 mouse embryonic fibroblasts were provided by A. Nussenzweig. All cells were cultured in the recommended media containing 10% fetal bovine serum and 10 U ml 21 penicillin/streptomycin (Gibco) and checked for mycoplasma by PCR or ELISA before experimental use.
Immunoblotting. The following antibodies were used according to manufacturer's instructions: rabbit anti-MTH1 (NB100-109, Novus Biologicals) 16 , rabbit anti-actin (AAN01, Cytoskeleton), mouse anti-tubulin (DM1A, Abcam), goat anti-p53 (C-19, Santa Cruz Biotechnology), goat Alexa Fluor 680 anti-mouse IgG (Life Technologies). Expression of recombinant MTH1. Codon-optimised human NUDT1 complementary DNA subcloned into a pETM-11 vector (G. Stier, EMBL) featuring a Histag and TEV site was obtained from GenScript (GenScript, NJ, USA) and expressed in the Escherichia coli strain BL21 DE3 (Life Technologies). After collecting, bacteria were lysed using buffer (50 mM Tris-HCl pH 7.5, 500 mM NaCl, 5% glycerol, 5 mM b-mercaptoethanol, 1 mM PMSF) containing lysozyme (Sigma-Aldrich) and DNase I (Roche). His-tagged protein was purified with NiNTA agarose (Qiagen), washed with buffer, and eluted with an imidazole gradient. Following removal of the His-tag by incubation with TEV protease, fractions were dialysed and purified using size-exclusion chromatography (Sephadex, GE Healthcare). Protein concentration of the purified fractions was determined by ultraviolet absorbance (A 280 nm ). The identity of the protein was confirmed by MALDI-TOF and protein activity determined by kinetic analysis which gave values in accordance with literature data 15 . MTH1 catalytic assay. Half-maximal inhibitory concentrations (IC 50 ) were determined using a luminescence-based assay as described previously 15 IC 50 values were determined by fitting a dose-response curve to the data points using nonlinear regression analysis using the GraphPad Prism software. siRNA experiments. Both a commercial MTH1-siRNA set (SMARTpool ON-TARGETplus, Dharmacon) as well as a custom-synthesized siRNA (Sigma-Aldrich) were obtained. The custom siRNA sequence was CGACGACAGCUACUGGUUU, AllStars Negative Control siRNA (Qiagen) was used as control. For transfections, cells were seeded in 24-well plates at approximately 30% confluency 24 h before siRNA treatment. The next day, medium was aspirated and transfections performed with INTERFERin (Polyplus) according to manufacturer's instructions using a final siRNA concentration of 10 nM. Cells were incubated for 2-3 days, washed, detached with trypsin and replated in six-well plates. After 7-10 days, medium was aspirated, cells were washed with PBS, fixed with ice-cold methanol, stained with crystal violet solution (0.5% in 25% methanol) and left to dry overnight. For quantification of results, ultraviolet absorbance of crystal violet was determined at 595 nm following solubilisation by 70% ethanol. Data were analysed using the GraphPad Prism software (t-test, P , 0.05). Target engagement assay. The ability of compounds to interact with, and thereby stabilize the target in intact cells, was analysed essentially as described by Molina et al. 24 . Briefly, BJ SV40T RASV12-cells cultured in T150 flasks to 80% confluency, were treated with cell media containing 1% DMSO and 5 mM either (R) or (S)crizotinib for 3 h. After treatment, cells were detached with trypsin, collected by centrifugation and subsequently resuspended in TBS. The cell suspension was aliquoted into eight PCR tubes and heated for 3 min to 47, 49, 51, 53, 54, 57, 59 or 61 uC. Subsequently, cells were lysed using liquid nitrogen and three repeated cycles of freeze-thawing. Precipitated proteins were separated from the soluble fraction by centrifugation at 17,000g for 20 min. Soluble proteins, collected in the supernatant, were kept at 280 uC until western blot analysis. Half of each aliquot was loaded onto 4-25% SDS-PAGE gels, blotted on nitrocellulose membranes and analysed using the MTH1-antibody from Novus Biologicals at a concentration of 1:500. Cloning of miR30-based shRNAs. To obtain inducible anti-p53-TRMPV-Neo miR30 shRNAs, pMLP plasmids containing p53-targeting sequences 33 were digested with EcoRI and XhoI, followed by ligation into the TRMPV-Neo vector 26 .
Retro-and lentivirus production. For stable knockdown and MTH1 overexpression studies, 293T cells were transfected with helper plasmids and either pBABEpuro (Addgene plasmid 1764) or pBabe puro MTH1 (Addgene plasmid 21295), pLKO-eGFP-shRNA-control, pLKO.1 shMTH1-1 (Addgene plasmid 21297), or pLKO.1 shMTH1-2 (Addgene plasmid 21298). SW480 cells were then treated with 48 h supernatants containing polybrene (8 mg ml 21 ) for 3 h. The next day cells were selected with puromycin (5 mg ml 21 ). Tet-on competent SW480 were established by transduction of cells with pMSCV-rtTA3-IRES-EcoR-PGK-PuroR 26 . After selection with puromycin (5 mg ml 21 ), cells were transduced with TRMPV-Neo-shRNAs using Plat-E cells and ecotropic packaging. After subsequent selection with G418 (1 mg ml 21 ) the expression of shRNAs was induced using doxycycline (2 mg ml 21 ) and monitored by FACS. Real-time PCR analysis. Total RNA was isolated using the RNeasy Mini Kit (Qiagen). 500 ng RNA was reverse transcribed using oligo(dT) primers using RevertAid Reverse Transcriptase (Fermentas). Quantitative PCR was carried out on a RotorGene RG-600 (Qiagen) PCR machine using the SensiMix SYBR kit (Bioline). Results were quantified using the 2 2DDC(t) method, using GAPDH expression levels for normalization. Primer sequences. NUDT1-F 59-CTCAGCGAGTTCTCCTGG -39; NUDT1-R 59-GGAGTGGAAACCAGTAGCTGTC-39. Colony formation assay. One day before treatment, 5 3 10 3 or 10 4 cells were seeded per well in six-well plates and incubated for 24 h. The next day DMSO (equal to highest amount of compound dilution, maximum 0.2%) or compounds in increasing concentrations were added and cells incubated at 37 uC, 5% CO 2 , for 7-10 days. After washing with PBS (Gibco), cells were fixed with ice-cold methanol, stained with crystal violet solution (0.5% in 25% methanol) and left to dry overnight. For quantification of results, ultraviolet absorbance of crystal violet was determined at 595 nm following solubilisation by 70% ethanol. Data were analysed using nonlinear regression analysis using the GraphPad Prism software. Proliferation rate measurements. Population doublings were determined as described 16 . Briefly, 10 5 cells were plated in triplicate in six-well plates followed by addition of drug or DMSO 6 h later and counting the number of cells every three days, after which 10 5 cells were replated for the next count. The numbers were converted into population doublings using the following formula: (log(no. of cells counted) 2 log(no. of cells plated))/log (2) . Comet assay. Cells were treated with compounds for 3 or 6 days, upon which DNA single-strand breaks were assayed using the comet assay under alkali conditions. For the H 2 O 2 control, cells were treated with H 2 O 2 (Sigma-Aldrich) in PBS at 150 mM for 10 min. Cells were washed twice with PBS, collected using a rubber scraper, pelleted by centrifugation, resuspended in PBS and mixed with 1% lowgelling-temperature agarose (Sigma type VII) that was maintained at 37 uC. The mixture of cells and agarose was layered onto frosted glass slides pre-coated with 0.5% agarose and slides were placed on ice to gel. Slides were maintained in the dark for all subsequent steps. Slides were immersed in pre-chilled lysis buffer (2.5 M NaCl, 0.1 M EDTA, 10 mM Tris-HCL pH 7.70, 1% Triton X-100, 1% DMSO) for 1 h, washed in pre-chilled distilled water 3 times for 20 min and incubated for 45 min in pre-chilled alkaline electrophoresis buffer (50 mM NaOH, 1 mM EDTA, 1% DMSO, pH 12.8). After electrophoresis for 25 min at 25 V, slides were placed at 4 uC overnight, in the dark. The following day, slides were neutralized with 0.4 M Tris-HCl pH 7.0 for 1 h and stained with SYBR Gold (Invitrogen, diluted 1:10,000 in distilled water) for 30 min. Comet tail moments (defined as the average distance migrated by the DNA multiplied by the fraction of DNA in the comet tail) were scored using the CellProfiler cell image analysis software. For the OGG1/MUTYH enzyme modified comet assay, 150,000 U2OS cells were seeded in triplicate on six-well plates. After overnight incubation, cells were treated either with buffer or (S)-crizotinib (5 mM) for 24 h. Cells (10 6 per ml) suspended in 1.2% low melting agarose were layered over the first layer of a 1% agarose gel on a frosted slide. Slides were then stored at 4 uC overnight in lysis buffer containing 100 mM sodium EDTA, 2.5 M NaCl, 10 mM Tris-HCl (pH 10), 1% Triton X-100 and 10% DMSO. After incubation, slides were washed 2 3 15 min each with enzyme buffer (40 mM HEPES, 0.1 M KCl, 0.5 mM EDTA and 0.2 mg ml 21 BSA, pH 8 adjusted with KOH). OGG1 or MUTYH in enzyme buffer were added on top and slides were incubated at 37 uC for 45 min. After incubation, alkaline denaturation with alkali buffer (300 mM NaOH, 1 mM sodium EDTA) was done in an electrophoresis chamber for 20 min. Electrophoresis was then conducted at 25 V and 300 mA in the same buffer for 30 min. Slides were later neutralised with neutralising buffer (250 mM Tris-HCl (pH 7.5)) for at least 30 min, and then stained with 20 mM YOYO-1 dye. Images were acquired with a confocal microscope and analysed using comet score software. Indirect immunofluorescence. Cells were treated with compounds for 3 days, following which they were adhered to glass coverslips, washed with PBS and then fixed with 3% paraformaldehyde in PBS for 20 min. Fixed cells were rinsed with PBS and permeabilized with 0.5% Triton-X-100 for 5 min. PBS washed slides
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were incubated for 1 h with 10% FCS and 0.1% Triton-X-100 in PBS following which cells were stained with an anti-53BP1 monoclonal antibody (H-300, Santa Cruz, diluted 1:600), in combination with an 8-oxoguanine antibody (2Q2311, AbCam, diluted 1:400), where indicated, in 10% FCS and 0.1% Triton-X-100 in PBS. After rinsing with PBS coverslips were incubated with an Alexa Fluor 568 goat anti-rabbit IgG secondary antibody in combination with an Alexa Fluor 488 anti-mouse IgM secondary antibody, where indicated, for 1 h (Invitrogen, diluted 1:400) in 10% FCS and 0.1% Triton-X-100 in PBS. After a PBS wash, DNA was counterstained with DAPI (Sigma-Aldrich) for 10 min and the coverslips were mounted in Fluorescent Mounting Medium (Dako). Images were analysed with a Zeiss fluorescent microscope at 363 magnification with supporting software. Xenograft study. All animals were acclimatised for one week, and had free access to water and food during the experiment. Animals were under a 12 h light cycle, and temperature, humidity and housing according to laboratory animal guidelines and regulations. The group size was based on previous experience on variability of tumour growth within control groups. Animals were grouped based on body weight, exclusion/inclusion criteria were pre-established in the ethical permit, and outliers in body weight were excluded. When assessing tumour volume, the experimenter was blinded. Tumour volume and body weight were analysed using two-way ANOVA (GraphPad Prism 4.0, GraphPad Software Inc.) and pairwise Bonferroni comparisons between groups, using a general linear model with repeat measures with experimental groups (treatment, control) as between factors and day as within-subject factor. Sidak's post hoc test was used for further analysis of significant interactions. SCID mice (female, 5-6 weeks, Scanbur, Germany, n 5 8 per group) were injected subcutaneously with 10 6 SW480 cells together with a matrix gel (1:1) in the sacral area. Treatment was initiated 1 day after cell inoculation. Vehicle or MTH1 inhibitor was administered subcutaneously once daily at 25 mg per kg for 35 days. MTH1 inhibitor was diluted in 1% DMSO, 10% ethanol, 10% Cremophor, 10% Tween 80, 69% PBS. Tumour size was measured twice weekly and body weight once weekly. At termination, a gross post-mortem inspection was performed; blood was collected for haematological parameters and aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT) and creatinine measurements. For oral dosing, SCID mice (female, 5-6 weeks, Scanbur, Germany, (S)-crizotinib group, n 5 8; (R)-crizotinib group, n 5 7; control group, n 5 8) were injected subcutaneously with 10 6 SW480 cells together with Matrigel (1:1) in the sacral area and two days later treatment was initiated. Vehicle, (S)-crizotinib or (R)-crizotinib were administered by oral gavage once daily for 26 days. The compounds were diluted in sterile water. Tumour size was measured twice weekly (calculated as length 3 width 3 width 3 0.52). The mice were weighed at least once weekly. At termination, a gross post-mortem inspection was performed. All experiments involving animals followed protocols approved by Stockholms Norra Djurförsöksetiska Nämnd (laboratory animal ethical committee Stockholm) and were in compliance with 2010/63/EU directive. Statistical analysis. Unless stated otherwise, a normal distribution of data was assumed and appropriate test were applied. ARTICLE RESEARCH
